Ovarian Cancer Coverage from Every Angle

Recent News

Ovarian Cancer and COVID-19: Protective Role for Antiestrogen Therapies?
Omental Metastasis: Predictive for Unfavorable Prognosis in Advanced Ovarian Cancer?
Japanese Study of Niraparib in Homologous Recombination–Deficient Ovarian Cancer
Oral Contraceptives and Risk of Ovarian Cancer
Combining Olaparib With Cediranib in Upcoming Ovarian Cancer Study
Case Study: Ovarian Cancer Disguised as Preeclampsia in a Pregnant Woman
FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers
Economic Analysis of Front-Line Maintenance Regimens for Ovarian Cancer
Pegylated Liposomal Doxorubicin Versus Gemcitabine in Recurrent Ovarian Cancer
Novel Chemoimmunotherapy Regimen Under Study in Recurrent Ovarian Cancer
Is Poor Sleep Quality Linked to Risk for Serous Ovarian Cancer in Older Women?
Does Risk for Second Primary Gynecologic Cancer Vary by Ethnicity in Ovarian Cancer?
Racial Disparities by Ovarian Cancer Subtypes in the United States
Is Single-Dose Intraoperative IP Carboplatin Feasible in Advanced Ovarian Cancer?
ESMO Asia 2020: SOLO1 Update on Olaparib Maintenance for BRCA-Mutated Ovarian Cancer
Serous Ovarian Cancer: Paclitaxel Dosing Comparison From VELIA Trial
Chemoimmunotherapy Triplet Under Study in Recurrent Ovarian Cancer
Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer
Resensitization of Ovarian Cancer to Carboplatin Using Oncolytic Vaccine
Fixed Versus Individual Starting Dose of Niraparib in Advanced Ovarian Cancer
Novel TIE2 Kinase Inhibitor Under Study in Platinum-Resistant Ovarian Cancer
Use of Bevacizumab Beyond Disease Progression in Platinum-Resistant Ovarian Cancer
Maintenance Olaparib in Advanced Ovarian Cancer: SOLO-1 Long-Term Survival Update
Immunochemotherapy Primed With Oncolytic Vaccinia Virus in Platinum-Resistant Ovarian Cancer
ESMO 2020: Impact of Rising CA-125 Levels in Treating Platinum-Sensitive Recurrent Ovarian Cancer
Ongoing Study of Afuresertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
ESMO 2020: Maintenance Niraparib in Older Patients With Advanced Ovarian Cancer
ESMO 2020: Overall Survival With Weekly Dose-Dense Chemotherapy for Ovarian Cancer
IGCS 2020: Lenvatinib Plus Pembrolizumab in Ovarian Cancer
ESMO 2020: Novel PARP Inhibitor Under Study in Advanced Ovarian Cancer
IGCS 2020: Addition of Veliparib to Carboplatin Paclitaxel in Newly Diagnosed Ovarian Cancer
ESMO 2020: Olaparib Plus Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
IGCS 2020: Paclitaxel Plus Tumor-Treating Fields for Platinum-Resistant Ovarian Cancer
Does Shifting to Ultra-Radical Surgery Improve Outcomes in Advanced Epithelial Ovarian Cancer?
IGCS 2020: Maintenance Immunotherapy for Stage III or IV Ovarian Cancer
IGCS 2020: Biomarker Analyses From JAVELIN Ovarian 100 Trial
Incomplete Pregnancy and Risk of Invasive Ovarian Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.